Vanguard Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Vanguard Group Inc. trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,048,269 shares of the biopharmaceutical company’s stock after selling 375,779 shares during the period. Vanguard Group Inc. owned approximately 8.54% of Regeneron Pharmaceuticals worth $5,087,570,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Brighton Jones LLC grew its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $226,000. Private Trust Co. NA boosted its position in shares of Regeneron Pharmaceuticals by 16.5% in the 2nd quarter. Private Trust Co. NA now owns 191 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 27 shares during the period. International Assets Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 30.0% during the 2nd quarter. International Assets Investment Management LLC now owns 724 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 167 shares during the last quarter. Finally, Cidel Asset Management Inc. increased its position in Regeneron Pharmaceuticals by 20.4% during the second quarter. Cidel Asset Management Inc. now owns 461 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 78 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 3,636 shares of company stock worth $2,862,920. Corporate insiders own 7.02% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of several research analyst reports. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Scotiabank raised their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Evercore upped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Finally, Citigroup raised their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $793.53 on Wednesday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The stock’s 50 day moving average is $766.18 and its two-hundred day moving average is $670.05. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The firm has a market capitalization of $83.89 billion, a PE ratio of 19.09, a P/E/G ratio of 2.16 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the firm earned $12.07 EPS. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 8.47%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.